Swedish Orphan Biovitrum AB

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000872095
SEK
343.00
5.2 (1.54%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

496.39 k

Shareholding (Mar 2024)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Healthy long term growth as Net Sales has grown by an annual rate of 12.34%

 
2

Positive results in Jun 25

3

With ROE of 11.90%, it has a attractive valuation with a 2.75 Price to Book Value

4

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

 
5

Consistent Returns over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 121,306 Million (Large Cap)

stock-summary
P/E

23.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.34

stock-summary
Return on Equity

19.23%

stock-summary
Price to Book

3.37

Revenue and Profits:
Net Sales:
6,175 Million
(Quarterly Results - Jun 2025)
Net Profit:
634 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.41%
0%
22.41%
6 Months
13.58%
0%
13.58%
1 Year
12.75%
0%
12.75%
2 Years
36.87%
0%
36.87%
3 Years
59.53%
0%
59.53%
4 Years
109.39%
0%
109.39%
5 Years
112.04%
0%
112.04%

Swedish Orphan Biovitrum AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.34%
EBIT Growth (5y)
8.66%
EBIT to Interest (avg)
6.87
Debt to EBITDA (avg)
1.73
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
0.45
Tax Ratio
12.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.02%
ROE (avg)
10.77%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.75
EV to EBIT
18.51
EV to EBITDA
11.77
EV to Capital Employed
2.36
EV to Sales
4.42
PEG Ratio
0.23
Dividend Yield
NA
ROCE (Latest)
12.73%
ROE (Latest)
11.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 13.47% vs 11.70% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 183.04% vs 0.90% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,175.00",
          "val2": "5,442.00",
          "chgp": "13.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,152.00",
          "val2": "1,555.00",
          "chgp": "38.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "216.00",
          "val2": "337.00",
          "chgp": "-35.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-237.00",
          "val2": "-30.00",
          "chgp": "-690.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "634.00",
          "val2": "224.00",
          "chgp": "183.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "204.50%",
          "val2": "117.60%",
          "chgp": "8.69%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.64% vs 17.74% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 61.02% vs -8.68% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "26,027.00",
          "val2": "22,124.00",
          "chgp": "17.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9,538.00",
          "val2": "7,825.00",
          "chgp": "21.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1,240.00",
          "val2": "1,111.00",
          "chgp": "11.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-195.00",
          "val2": "-484.00",
          "chgp": "59.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3,879.00",
          "val2": "2,409.00",
          "chgp": "61.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "223.40%",
          "val2": "210.50%",
          "chgp": "1.29%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
6,175.00
5,442.00
13.47%
Operating Profit (PBDIT) excl Other Income
2,152.00
1,555.00
38.39%
Interest
216.00
337.00
-35.91%
Exceptional Items
-237.00
-30.00
-690.00%
Consolidate Net Profit
634.00
224.00
183.04%
Operating Profit Margin (Excl OI)
204.50%
117.60%
8.69%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 13.47% vs 11.70% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 183.04% vs 0.90% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
26,027.00
22,124.00
17.64%
Operating Profit (PBDIT) excl Other Income
9,538.00
7,825.00
21.89%
Interest
1,240.00
1,111.00
11.61%
Exceptional Items
-195.00
-484.00
59.71%
Consolidate Net Profit
3,879.00
2,409.00
61.02%
Operating Profit Margin (Excl OI)
223.40%
210.50%
1.29%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 17.64% vs 17.74% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 61.02% vs -8.68% in Dec 2023

stock-summaryCompany CV
About Swedish Orphan Biovitrum AB stock-summary
stock-summary
Swedish Orphan Biovitrum AB
Pharmaceuticals & Biotechnology
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Company Coordinates stock-summary
Company Details
Tomtebodavagen 23A , SOLNA None : 112 76
stock-summary
Tel: 46 8 697200046 73 3666599
stock-summary
Registrar Details